|Podcasts|March 3, 2022
Respiratory Issues
Author(s)Elaine Quilici, Miranda Schmalfuhs
In episode 103, Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.
Advertisement
In episode 103, Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Generates $1.5 Billion Stockpile of Orforglipron Ahead of FDA Decision
2
Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
3
Pharm Exec's 2026 Pipeline Report: Next Frontiers in Focus
4
Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care
5